Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 23.1% in January

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the target of a large drop in short interest in January. As of January 15th, there was short interest totalling 47,300 shares, a drop of 23.1% from the December 31st total of 61,500 shares. Based on an average daily volume of 122,300 shares, the days-to-cover ratio is currently 0.4 days.

Entera Bio Stock Performance

Shares of NASDAQ:ENTX traded up $0.01 during midday trading on Thursday, hitting $2.39. The company's stock had a trading volume of 60,888 shares, compared to its average volume of 240,997. The stock's 50 day simple moving average is $2.16 and its 200 day simple moving average is $1.91. Entera Bio has a fifty-two week low of $0.68 and a fifty-two week high of $3.35. The stock has a market capitalization of $85.51 million, a price-to-earnings ratio of -9.19 and a beta of 1.49.

Institutional Trading of Entera Bio

Institutional investors have recently modified their holdings of the company. Perigon Wealth Management LLC acquired a new stake in Entera Bio in the 4th quarter valued at $325,000. Signature Estate & Investment Advisors LLC acquired a new position in shares of Entera Bio in the 3rd quarter worth approximately $90,000. Finally, Parkman Healthcare Partners LLC increased its stake in shares of Entera Bio by 2.4% in the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company's stock valued at $781,000 after buying an additional 9,558 shares in the last quarter. Institutional investors and hedge funds own 14.11% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Entera Bio in a research report on Monday, November 11th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.